At the beginning of January 2017 BioM launched the InnoMuNiCH project to promote cooperation between the Japanese biopharmaceutical industry and the biotechnology companies of the Munich Biotechnology Cluster . BioM successfully applied for funding as part of the "Internationalization of Leading-Edge Clusters " program. The German Federal Ministry of Education and Research (BMBF) funds the project and promotes a two-year concept phase. During this time, BioM will establish a collaborative platform to facilitate access to the Japanese biopharmaceutical research industry.
The first step will be to develop specific binational projects, together with a group of Bavarian companies, co-funded by the BMBF. These will act as a basis for strengthening German-Japanese relations as well as a foundation for the Munich Biotech Cluster’s strategy for internationalization in Japan.
IMGM is very proud to be a partner company for this project and will develop a concept for a German-Japanese research project in the coming months. For this purpose, IMGM has put together a project team that has developed various research options and then transferred them, together with BioM and other Bavarian companies, into a binational initiative.
IMGM Laboratories GmbH announces Illumina Propel Certification for NextSeq 500/550
IMGM Laboratories GmbH has successfully completed the Illumina Propel certification for NextSeq 500/550, gaining entry into an elite group of global Illumina genomics service providers. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
Illumina Propel is a collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Propel Certification provides a competitive advantage for service providers and enables customers selecting Illumina Propel-Certified facilities to feel confident that they are receiving the excellent data quality, insight, and service they have come to expect from Illumina.
Gene Therapy can recuperate hearing in mice
A gene therapy vector, Anc80, developed at Massachusetts Eye and Ear has been shown to deliver the correct version of the gene USH1C to both the outer and inner hair cells of the ear. A mutation of this gene is known to cause deaf-blindness.
A further study showed that mice with a mutation in USH1C that were treated with the synthetic gene therapy vector directly after birth, began to hear.
This story is just one example that clearly shows the high potential of gene therapy methods to treat genetic diseases.
If you are working in the field of gene therapy, IMGM’s GLP-compliant biodistribution service is of interest. Here we offer the absolute quantification of a nucleic acid compound, like a gene therapy vector, in various tissues of a model organism in the course of a preclinical safety and toxicology study.
IMGM is a leading genomic service provider with a focus on Biomarker Discovery, Biodistribution, Pharmacogenetics and Metagenomics. With NGS, microarray and qPCR state-of-the-art technology, as well as competency in complex data analysis, the company offers complete tailored solutions to customers from pharma, diagnostics, biotech and academia. Quality, experience, motivation and a strong background in molecular genetics and medical diagnostics make IMGM a valuable partner for genetic analysis in pre-clinical and clinical studies.
Get in touch with our team via our contact sheet or call +49.89.4524667.0. For more information on IMGM’s service portfolio check out our homepage www.IMGM.com